• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, October 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Chemotherapy drug more effective when combined with microbubbles

Bioengineer by Bioengineer
September 8, 2020
in Biology
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Administering a smaller, less toxic dose of DOX, along with intravenous perfluocarbon, shows tumor regression, reduces recurrence, and is less invasive than common treatments

IMAGE

Credit: Jonah S. Harmon

WASHINGTON, September 8, 2020 — Hepatocellular carcinoma is a particularly stubborn form of cancer with few treatments and a high mortality rate. It is usually treated by blocking the flow of blood to the tumor to induce cancer cell death. The common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method.

Aiming to increase the precision, researchers at Tulane University created a combination treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine that is used in pharmaceuticals, anesthetics, and industrial fluids. The method of gas embolization, published in APL Bioengineering, by AIP Publishing, is relatively new, and it is the authors’ specialty.

“By changing the treatment parameters in this paper, we were able to achieve tumor regression, and by combining our method with chemotherapy, we were able to reduce regrowth following treatment,” author Joseph Bull said. “Gas embolization has never been used in patients. Demonstrating that it can induce tumor regression is really new. We’re very excited about the work in this paper.”

Their study tested gas embolization alone and in combination with two common cancer drugs, doxorubicin (DOX) and tirapazamine. Gas embolization stops blood flow to the tumor, and it was highly effective used in combination with DOX.

In the gas embolization method, perfluorocarbon liquid is administered intravenously, and it interacts with DOX that has been administered in the body. DOX binds to the surface of the droplets of liquid, which are small enough to travel through capillaries and do not cause blood vessel blockage until they are vaporized, so treatment can be applied at the specific site of the tumor.

To turn these tiny liquid droplets into microbubbles and cut off the blood flow to the tumor, ultrasound is applied from outside the body. The fluid mechanical interface of the droplet focuses the ultrasound in a cavitationlike event, in which gas bubbles inside the liquid droplet grow due to a drop in pressure, until the droplet turns completely into microbubbles.

The drug DOX binds to the shell of the droplet, and the medicine becomes available to diffuse into the tumor, while the microbubbles cut off blood supply to the tumor.

The combination of gas embolization and DOX was so effective that, on average, tumors shrank to 2.9% of their initial size, while using DOX alone slowed tumor growth but still allowed them to grow to 300% of their initial size.

###

The article, “Combined gas embolization and chemotherapy can result in complete tumor regression in a murine hepatocellular carcinoma model,” is authored by Jonah S. Harmon, Foad Kabinejadian, and Joseph L. Bull. The article appears in APL Bioengineering on Sept. 8, 2020 (DOI: 10.1063/5.0005329) and be accessed at https://aip.scitation.org/doi/10.1063/5.0005329.

ABOUT THE JOURNAL

APL Bioengineering is an open access journal publishing significant discoveries specific to the understanding and advancement of physics and engineering of biological systems. See http://aip.scitation.org/journal/apb.

Media Contact
Larry Frum
[email protected]

Related Journal Article

http://dx.doi.org/10.1063/5.0005329

Tags: BiologyBiomechanics/BiophysicscancerCell BiologyChemistry/Physics/Materials SciencesMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Sex Differences in Social Health Drivers and Interventions

October 22, 2025
blank

Long-Read Metagenomics Tracks Strains Post-Transplant

October 22, 2025

Unraveling the Psoas Major: Pig Muscle Quality Insights

October 22, 2025

Decoding the Science Behind Aging

October 22, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1273 shares
    Share 508 Tweet 318
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    305 shares
    Share 122 Tweet 76
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    143 shares
    Share 57 Tweet 36
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    131 shares
    Share 52 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

MRI Links Body Compartments to Metabolic Traits

Segmental Cholestasis Sparks Widespread Liver Fibrosis

Gold Price Predictions with LSTM-Autoencoder Hybrid Model

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.